RRML - Monitoring T315I mutation in chronic myeloid leukemia by amplification refractory mutation system PCR
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12


Advanced search


Top 10 downloaded articles
- February 2024 -
 
Anti-thyroid peroxidase (TPO) ... 18
Romanian Review of Laboratory ... 17
Approaching Risk Management in... 13
Recomandarea comună EFLM-COLA... 13
Identification of shared hub g... 13
Challenges in prophylactic the... 13
Monocyte to high-density lipop... 10
Atellica CH 930 chemistry anal... 8
Understanding the key differen... 8
Setting up an own laboratory p... 7

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 13(4)/2008
XML
TXT

Monitoring T315I mutation in chronic myeloid leukemia by amplification refractory mutation system PCR

Delia Dima, Adrian P Trifa, Andrei Cucuianu, Radu A Popp, Mariana Paţiu, Ljubomir Petrov


Abstract:

The introduction of imatinib mesylate has revolutionized the treatment of chronic myeloid leukemia. Even though experience with imatinib mesylate is limited, clinical resistance has already been observed. In order to overcome imatinib resistance, more potent tyrosine kinase inhibitors such as nilotinib and dasatinib have been developed, with demonstrable activity against most BCR-ABL domain mutations with the notable exception of T315I mutation. Moreover, with the increased use of newer tyrosine kinase inhibitors it has been suggested that the spectrum of mutations may change, possibly selecting the pan-resistant T315I. That is why mutational analy­sis should be done on a regular basis or at any time the clinical and hematological aspects change, in order to give the patient the best therapy available.

Keywords: imatinib,tyrosine kinase,mutation,T315I

 
  PDF Download full text PDF
(66 KB)
     
 
How to cite
Dima D, Trifa AP, Cucuianu A, Popp RA, Paţiu M, Petrov L. Monitoring T315I mutation in chronic myeloid leukemia by amplification refractory mutation system PCR. Rev Romana Med Lab. 2008;13(4):17-20